LUCA Science Inc.
Tomoyuki Inoue currently serves as the Head of CMC at LUCA Science Inc. since February 2022. Prior to this role, Tomoyuki held various positions at Megakaryon Corporation from January 2014 to January 2022, including Executive Officer and General Manager of CMC, as well as Director of the Kyoto Development Center. Tomoyuki's career in bioprocess development began at Chugai Pharmaceutical Corporation, where service was provided from September 2006 to December 2013. Tomoyuki holds a PhD in Technical Biology (Microbiology) from the University of Stuttgart, acquired between 2003 and 2006, and a Master's degree in Biotechnology from the Tokyo Institute of Technology, completed from 1996 to 1998.
This person is not in any teams
This person is not in any offices
LUCA Science Inc.
LUCA Science is at the forefront of a new kind of mitochondrial therapy that aims to restore cellular bioenergetics in malfunctioning or damaged tissues and organs. Using our patented iMIT technology, LUCA Science is creating a novel platform of highly functional mitochondria. We could boost bioenergetics and restore normal activities by supplyingintact and functional mitochondria to the affected tissues. The utilization of mitochondria as a biopharmaceutical agent would be groundbreaking for treating a wide range of unmet medical needs.